Your session is about to expire
← Back to Search
Procedure
Normothermic Machine Perfusion for Liver Transplant
N/A
Recruiting
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age 18-80 years
Be older than 18 years old
Must not have
MELD < 15 and asymptomatic from liver disease
History of cardiac or pulmonary disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed at 3, 6, and 12 months post-transplant
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to test if using a process called Normothermic Machine Perfusion can improve the quality of moderately fatty livers for transplantation. The study will involve placing livers with 30-60
Who is the study for?
This trial is for adults aged 18-80 who are on the liver transplant list at MGH with a MELD-Na score of 25 or less and can give consent. It's not suitable for those outside this age range, with higher MELD-Na scores, or unable to consent.
What is being tested?
The study tests if Normothermic Machine Perfusion (NMP) can make moderately fatty livers safe for transplant by keeping them functioning at normal body temperature after donation and before transplantation.
What are the potential side effects?
While the trial focuses on improving liver viability, potential side effects may relate to how well the transplanted liver functions post-surgery and could include typical transplant complications.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 80 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My liver is functioning well enough (MELD score below 15) and I don't have symptoms from liver disease.
Select...
I have a history of heart or lung disease.
Select...
I have had a liver transplant in the past.
Select...
I need medication to maintain my blood pressure due to liver issues.
Select...
I am in urgent need of a transplant.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ assessed at 3, 6, and 12 months post-transplant
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed at 3, 6, and 12 months post-transplant
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Early allograft dysfunction
Secondary study objectives
30-day patient survival
Additional procedures
Adverse events
+25 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Liver Transplantation with Steatotic LiverExperimental Treatment1 Intervention
Graft will be selected if 30-60% macrosteatosis and transplanted into liver transplant recipient with MELD of 15-25.
Find a Location
Who is running the clinical trial?
Massachusetts General HospitalLead Sponsor
3,026 Previous Clinical Trials
13,413,620 Total Patients Enrolled